Fujii Yoshitaka, Nakayama Masahiro
First Department of Anesthesiology, Toho University School of Medicine, Tokyo, Japan.
Department of Anesthesiology, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Japan.
Clin Ther. 2007 May;29(5):856-861. doi: 10.1016/j.clinthera.2007.05.019.
Pain on injection is a recognized adverse event (AE) with propofol, an agent used to induce general anesthesia in surgical patients. Lidocame (LID) has been found efficacious in reducing pain on injection of propofol; however, this type of pain may not be completely eliminated with LID. Metoclopramide (MET) is a dopamine receptor agonist with antiemetic and prokinetic properties used for the treatment of nausea and facilitation of gastric emptying in patients with gastroparesis. MET also has local anesthetic properties similar to those of LID.
The aim of this study was to examine the effects of LID administered with 3 different doses of MET or saline on pain on injection of propofol in Japanese adults undergoing elective surgery.
This randomized, double-blind study was conducted at the Department of Anesthesiology, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Japan. Japanese patients aged 20 to 67 years who were scheduled to undergo elective surgery were eligible for participation. Patients were randomized to receive N administration of LID 40 mg + MET 2.5, 5, or 10 mg or saline. A rubber tourniquet was used to perform 1 minute of venous occlusion before administration of the study and control drugs, and then 25% of the total calculated dose of propofol (2 mg/kg) was injected into the dorsal vein of the hand through a 20-G N cannula at a rate of 1 mL/s. During a 10-second pause before the induction of anesthesia, patients were questioned by a blinded investigator about the pain intensity on injection. Pain intensity was assessed through the use of a 4-point verbal rating scale, with scores ranging from 0 (no pain) to 3 (severe pain). Incidence and intensity of pain (as assessed by mean pain scores) were determined in each of the 4 study groups. Extrapyramidal reactions and injection-site AEs, including pain, edema, wheals, and inflammation occurring up to 24 hours after surgery were recorded by a blinded investigator.
The study enrolled 240 patients (126 men, 114 women; mean [SD] age, 43 [13] years [range, 20-67 years]; mean [SD] height, 160 [8] cm [133-181 cm]; mean [SD] body weight, 57 [10] kg [range, 33-85 kg]). There were 60 patients randomized to each of the 4 study groups, which were comparable in distribution of demographic characteristics. Incidence of propofol-induced pain was significantly lower, but the intensity of pain was not less, in the groups that received LID/MET 40/5 or 40/10 (both, 5%) compared with those who received LID/MET 40/2.5 or LID/saline (18% and 20%, respectively) (all, P < 0.05). There were no reports of injection-site AEs or extrapyramidal reactions after injection of the control or study drugs in any of the study groups.
Among these 240 Japanese patients undergoing elective surgery, N administration of LID/MET 40/5 or 40/10 was associated with lower incidence, but not lower mean pain intensity scores, of pain on injection of propofol than LID/MET 40/2.5 or LID/saline before induction of anesthesia.
注射痛是丙泊酚(一种用于外科手术患者诱导全身麻醉的药物)公认的不良事件(AE)。已发现利多卡因(LID)能有效减轻丙泊酚注射痛;然而,使用LID可能无法完全消除此类疼痛。甲氧氯普胺(MET)是一种多巴胺受体激动剂,具有止吐和促动力特性,用于治疗恶心以及促进胃轻瘫患者的胃排空。MET还具有与LID类似的局部麻醉特性。
本研究旨在探讨LID与3种不同剂量的MET或生理盐水联合使用对择期手术日本成年人丙泊酚注射痛的影响。
本随机、双盲研究在日本筑波大学临床医学院麻醉科进行。年龄在20至67岁、计划接受择期手术的日本患者符合参与条件。患者被随机分为接受40mg LID + 2.5mg、5mg或10mg MET或生理盐水注射的组。在给予研究药物和对照药物前,使用橡胶止血带进行1分钟的静脉闭塞,然后通过20G套管以1mL/s的速度将计算出的丙泊酚总剂量(2mg/kg)的25%注入手背静脉。在诱导麻醉前的10秒暂停期间,由一位盲法研究者询问患者关于注射时的疼痛强度。疼痛强度通过4分言语评定量表进行评估,分数范围从0(无疼痛)至3(重度疼痛)。在4个研究组中分别确定疼痛的发生率和强度(通过平均疼痛评分评估)。由一位盲法研究者记录术后24小时内发生的锥体外系反应和注射部位不良事件,包括疼痛、水肿、风团和炎症。
该研究纳入了240例患者(126例男性,114例女性;平均[标准差]年龄,43[13]岁[范围,20 - 67岁];平均[标准差]身高,160[8]cm[133 - 181cm];平均[标准差]体重,57[10]kg[范围,33 - 85kg])。4个研究组每组随机分配60例患者,其人口统计学特征分布具有可比性。与接受LID/MET 40/2.5或LID/生理盐水(分别为18%和20%)的组相比,接受LID/MET 40/5或40/10(均为5%)的组中丙泊酚诱导的疼痛发生率显著更低,但疼痛强度并未减轻(均为P < 0.05)。在任何研究组中,注射对照药物或研究药物后均未报告注射部位不良事件或锥体外系反应。
在这240例接受择期手术的日本患者中,与麻醉诱导前接受LID/MET 40/2.5或LID/生理盐水相比,给予LID/MET 40/5或40/10可使丙泊酚注射痛的发生率更低,但平均疼痛强度评分并未降低。